1

Genetic Technologies

#9987

Rank

$3.71M

Marketcap

AU Australia

Country

Genetic Technologies
Leadership team

Mr. Simon Morriss (Chief Exec. Officer)

Mr. Carl S. Stubbings BSc (Chief Commercial Officer)

Mr. Tony Di Pietro AGIA, B.Com, C.A., CPA, M.A.I.C.D. (CFO & Company Sec.)

Products/ Services
Biotechnology, Genetics, Health Care, Medical
Number of Employees
50 - 100
Headquarters
Fitzroy, Victoria, Australia
Established
1987
Company Registration
SEC CIK number: 0001166272
Revenue
5M - 20M
Traded as
GENE
Social Media
Overview
Location
Summary
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, and type 2 diabetes. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.
History

Genetic Technologies, Ltd. was founded in 1984 in Australia. It was first listed on the Australian Stock Exchange in 1987 and then was listed on NASDAQ in 2014. In May 2015, the company acquired Premaitha Health, a United Kingdom-based molecular diagnostic technology company.

Mission
Genetic Technologies strives to provide the highest quality genetic testing that is accessible, reliable and accurate. We are committed to improving healthcare and empowering individuals with knowledge of their risk of developing diseases.
Vision
Our vision is to be the number one provider of innovative, accurate and cost-effective diagnostic testing solutions that provide people with the knowledge they need to lead healthier lives.
Key Team

Mr. Kevin Camilleri (Chief Exec. Officer of EasyDNA)

Mr. Paul Keith Mathieson Viney B. Bus, FCI, FCPA, FGIA (Consultant)

Recognition and Awards
Genetic Technologies has been recognized for excellence with numerous awards, including the Analytical Instrumentation and Life Sciences Award by Frost & Sullivan in 2016, the Australian Technology Company of the Year Award in 2017, and the Forum Company of the Year Award in 2018.
References

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Genetic Technologies
Leadership team

Mr. Simon Morriss (Chief Exec. Officer)

Mr. Carl S. Stubbings BSc (Chief Commercial Officer)

Mr. Tony Di Pietro AGIA, B.Com, C.A., CPA, M.A.I.C.D. (CFO & Company Sec.)

Products/ Services
Biotechnology, Genetics, Health Care, Medical
Number of Employees
50 - 100
Headquarters
Fitzroy, Victoria, Australia
Established
1987
Company Registration
SEC CIK number: 0001166272
Revenue
5M - 20M
Traded as
GENE
Social Media